3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
NCT01183897
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Neuroblastoma
Interventions
BIOLOGICAL:
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
Sponsor
Memorial Sloan Kettering Cancer Center